Skip to main content

Table 5 Treatment-emergent adverse events (all events that occurred in >1 subject)

From: Safety and pharmacodynamic dose response of short-term prednisone in healthy adult subjects: a dose ranging, randomized, placebo-controlled, crossover study

TEAE TEAEs, n (%)
  Prednisone (mg/day)
Placebo 2.5 5 10 20 40 60
(n = 15) (n = 15) (n = 15) (n = 15) (n = 16) (n = 15) (n = 16)
Total 10 (67) 6 (40) 5 (33) 2 (13) 8 (50) 3 (20) 4 (25)
Headache 4 (27) 4 (27) 1 (7) 0 4 (25) 2 (13) 3 (19)
Nasopharyngitis 1 (7) 0 2 (13) 1 (7) 0 0 1 (6)
Pharyngolaryngeal pain 0 1 (7) 1 (7) 0 1 (6) 1 (7) 0
Cough 0 0 1 (7) 1 (7) 1 (6) 0 0
Dyshidrosis 1 (7) 0 0 0 1 (6) 1 (7) 0
Dyspepsia 0 0 1 (7) 0 1 (6) 1 (7) 0
Abdominal pain, upper 0 1 (7) 0 0 0 0 1 (6)
Dermatitis, contact 0 1 (7) 1 (7) 0 0 0 0
Dizziness 1 (7) 0 0 0 0 0 1 (6)
Dysmenorrhea 0 0 0 0 1 (6) 0 1 (6)
Furuncle 1 (7) 0 1 (7) 0 0 0 0
Nausea 0 0 0 0 0 1 (7) 1 (6)
Pyrexia 1 (7) 0 1 (7) 0 0 0 0
  1. TEAE treatment-emergent adverse event